注射用地西他滨不同给药剂量/方案治疗骨髓增生异常综合征(MDS)有效性和安全性的开放、多中心Ⅳ期临床研究
[Translation] An open, multicenter phase IV clinical study on the efficacy and safety of different dosing regimens of decitabine for injection in the treatment of myelodysplastic syndrome (MDS)
评价连云港杰瑞药业有限公司生产的注射用地西他滨(50mg)在不同给药剂量/方案下,治疗骨髓增生异常综合征 (MDS)的有效性和安全性,为优化临床给药方案提供依据。
[Translation] To evaluate the efficacy and safety of decitabine for injection (50 mg) produced by Lianyungang Jereh Pharmaceuticals Co., Ltd. in the treatment of myelodysplastic syndrome (MDS) at different dosages/schemes, and to provide a basis for optimizing clinical dosing regimens.
100 Clinical Results associated with Jari Pharmaceutical Co Ltd
0 Patents (Medical) associated with Jari Pharmaceutical Co Ltd
100 Deals associated with Jari Pharmaceutical Co Ltd
100 Translational Medicine associated with Jari Pharmaceutical Co Ltd